Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis

Table 2

Meta-analysis of association between rs25487 or rs1799782 and efficacy of NSCLC treated with platinum-based chemotherapy in Asians.

XRCC1	ORR				OS				PFS
	No.	(%)	OR (95% CI)		No.	(%)	HR (95% CI)		No.	(%)	HR (95% CI)
rs25487 (Arg399Gln)^$
Homozygous model	17	56.8	1.71 (1.16-2.52)	.007	12	63.2	0.60 (0.40-0.88)	.009	4	24.4	0.64 (0.46-0.90)	.010
Heterozygous model	17	29.0	1.23 (1.07-1.40)	.003	12	63.2	0.81 (0.64-1.03)	.083	4	0	0.87 (0.71-1.07)	.193
Dominant model	20	69.3	1.11 (0.87-1.41)	.386	5	39.4	1.00 (0.79-1.27)	.980	4	0	0.87 (0.71-1.08)	.215
Recessive model	18	54.2	1.45 (1.02-2.06)	.037	3	13.8	1.14 (0.82-1.59)	.490	—	—	—	—
rs1799782 (Arg194Trp)^#
Homozygous model	9	34.0	1.73 (1.31-2.27)	<.001	10	53.4	0.63 (0.43-0.91)	.013	4	0	0.93 (0.68-1.26)	.627
Heterozygous model	9	0	1.28 (1.06-1.55)	.007	10	0	0.89 (0.70-1.05)	.173	4	0	1.02 (0.83-1.26)	.838
Dominant model	9	25.5	1.38 (1.16-1.65)	<.001	4	0	0.91 (0.71-1.16)	.446	3	0	1.05 (0.83-1.34)	.662
Recessive model	9	12.5	1.56 (1.20-2.03)	<.001	—	—	—	—	—	—	—	—

^$Homozygous, heterozygous, dominant, and recessive models indicated GlnGln vs. ArgArg, GlnArg vs. ArgArg, GlnGln+GlnArg vs. ArgArg ,and GlnGln vs. GlnArg+ArgArg, respectively. ^#Homozygous, heterozygous, dominant, and recessive models indicated TrpTrp vs. ArgArg, TrpArg vs. ArgArg, TrpTrp+TrpArg vs. ArgArg, and TrpTrp vs. TrpArg+ArgArg, respectively. Abbreviations: NSCLC: non-small-cell lung cancer; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; OR: odds ratio; HR: hazard ratio.